A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer

Table 4 Characteristics of patients who received anti-EGFR therapy

Characteristics		All WT^a	Any MT^b	Pvalue
Characteristics		(n= 56, %)	(n= 10, %)	Pvalue
Age	Median (range)	64 (34–79)	64 (51–74)	0.629*
ECOG PS	0	38 (67.9)	3 (30.0)	0.034**
ECOG PS	1–2	18 (32.1)	7 (70.0)
Primary lesion	Colon	35 (62.5)	5 (50.0)	0.498**
Primary lesion	Rectum	21 (37.5)	5 (50.0)
Histology	Well, mod	53 (94.6)	8 (80.0)	0.162**
Histology	Por, muc	3 (5.4)	2 (20.0)
Number of metastasis	1	14 (25.0)	4 (40.0)	0.442**
Number of metastasis	>2	42 (75.0)	6 (60.0)
Treatment line of anti-EGFR mab	2nd line	27 (48.2)	3 (30.0)	0.327**
Treatment line of anti-EGFR mab	3rd line	29 (51.8)	7 (70.0)
Treatment	Combination therapy	44 (78.6)	3 (30.0)	0.004**
Treatment	Monotherapy	12 (21.4)	7 (70.0)
Gene mutation	KRAS codon 61, 146	-	3
	NRAS codon12, 13, 61	-	2
	PIK3CA exon 9, 20	-	3
	BRAF codon 600	-	3

*Mann–Whitney U test; **χ² or Fisher exact test. ^aWild type KRAS codons 61, 146, NRAS, BRAF and PIK3CA; ^bany mutations in KRAS codons 61 or 146, NRAS, BRAF or PIK3CA. mab: monoclonal antibody.

ISSN: 1471-2407